Key Highlights

  • IN8bio's Phase 1 glioblastoma data, published in the Journal of Clinical Oncology, showed repeat-dose patients achieving median progression-free survival of 16.1 months versus roughly 6.9 months for the standard-of-care benchmark.
  • A later ASCO update showed 43% of patients alive at 24 months versus 20% for contemporaneous controls, with no dose-limiting toxicities or serious immune-related adverse events across all studies.
  • Despite the encouraging data, the company's Q2 filing carries a going-concern warning, with $18.0 million in cash covering under four quarters at the current burn rate, and a $20.1 million financing Tranche contingent on unrelated preclinical milestones rather than guaranteed.

IN8bio, Inc. (NASDAQ:INAB) is a small New York biotech built around gamma-delta T cells - an uncommon immune cell that attacks tumours without the tissue-matching signals conventional T cells need. It engineers them to survive chemotherapy, a platform called DeltEx DRI, and is testing them in newly diagnosed glioblastoma.

Two events have drawn attention. On 9 July 2026 the company said its Phase 1 data had been published in The Journal of Clinical Oncology. On 6 August it filed second-quarter results showing $18.0 million of cash - and a 10-Q stating substantial doubt about its ability to continue as a going concern.

The gap between the science and the Balance Sheet is the story: MarketBeat put the Market Capitalisation near $11.6 million in mid-August, against an accumulated Deficit of $151.0 million.

What Happened

IN8bio reported second-quarter results on 6 August via Form 8-K. Cash was $18.0 million at 30 June, down from $21.9 million at 31 March and $27.1 million at the end of 2025. Net loss narrowed to $4.8 million, or $0.25 a share, from $5.1 million.

The Journal of Clinical Oncology paper covered the Phase 1 INB-200 study, in which 13 newly diagnosed glioblastoma patients received one, three or up to six doses of DeltEx DRI alongside standard treatment. Repeat-dose patients showed median progression-free survival - the time before a tumour regrows - of 16.1 months against roughly 6.9 months for the standard-of-care benchmark; across all 13 it was 9.9 months.

A later analysis presented at ASCO on 1 June 2026, with a 15 May data cut, covered 17 repeat-dose patients versus contemporaneously enrolled controls: median overall survival beyond 19.5 months and not yet reached, against 13.2 months; median progression-free survival of 13.0 versus 6.6 months; and 43% alive at 24 months against 20%.

In both, the company reported no dose-limiting toxicities, no cytokine release syndrome and no ICANS - the immune over-reaction and neurological side effects that often accompany engineered cell therapies.

Why It Matters

Glioblastoma care has barely changed since 2005. The Stupp regimen - surgery, chemotherapy with radiation, then maintenance temozolomide - has historically delivered median survival of roughly 14.6 months, and many well-funded programmes have failed to beat it.

Cell therapy has also struggled in solid tumours: CAR-T transformed several blood cancers but stalls against tumour masses that suppress immune attack. IN8bio's engineering makes its cells resistant to the chemotherapy patients already receive, so both can be given at once.

Translational work reported an 18-fold rise in intratumoral CD8+ T cell density and a 90% fall in immunosuppressive granulocytes - more cancer-killing cells inside the tumour, fewer shielding it. The caveat is scale: Phase 1 cohorts of 13 and 17 patients measured against control groups, not a randomised trial.

The Numbers

Second-quarter R&D expense was $2.5 million, flat year on year, with G&A of $2.4 million against $2.7 million. Six-month operating expenses totalled $10.2 million, split almost evenly between the two, for a half-year net loss of $9.871 million, or $0.51 a share.

Burn is near $4.9 million a quarter, so $18.0 million is under four quarters of runway. There were 9,858,383 common shares outstanding on 3 August, after a one-for-30 reverse split in June 2025, plus 9,620,002 pre-funded warrants exercisable at $0.0001 to $0.003.

The December 2025 private Placement led by Coastlands Capital closed a first tranche of $20.1 million, netting $18.5 million. A second tranche of roughly $20.1 million - up to 14,579,706 shares or pre-funded warrants - is contingent on CD19-targeting preclinical milestones for INB-619, the next-generation gamma-delta T cell engager.

The at-the-market Facility is barely used: 6,032 shares sold in the first half for about $10,000 net, with $2.8 million left at 30 June. On 1 June the company signed a Capital on Demand agreement with JonesTrading at 3.0% commission, replacing its Cantor Fitzgerald arrangement.

What It Means for the Company

The financing design matters most. By tying the second $20.1 million tranche to preclinical milestones rather than a share price, IN8bio can roughly double its cash without going to the open market - if the data land. That makes an early-stage laboratory readout, not the brain-cancer programme, the near-term determinant of the balance sheet.

Management has cut hard. Full-year 2025 net loss fell to $19.4 million from $30.4 million, with R&D down to $10.2 million from $17.0 million and G&A to $9.7 million from $12.6 million.

The publication and ASCO presentation give IN8bio validation to carry into regulatory talks. It says it is discussing accelerated pathways for DeltEx DRI with the FDA, and a Phase 2 multi-centre study, INB-400, is running across US brain tumour centres.

Risks Investors Should Watch

Funding is the dominant risk, as the going-concern language concedes. If the INB-619 milestones slip, the alternatives are an Equity raise into a roughly $12 million market capitalisation, a partnership, or cuts.

Dilution is already heavy. The 9.6 million pre-funded warrants nearly double the effective share count, and the second tranche could add up to 14.6 million more shares against 9.86 million outstanding.

Listing risk deserves monitoring. Nasdaq requires a $1.00 minimum bid and the shares traded as low as $0.88 over the past 52 weeks. No deficiency notice was disclosed in the second-quarter report, but the reverse-split remedy has been used once.

Clinical and Regulatory Risk stays high: small non-randomised cohorts, no guarantee from FDA discussions, and autologous cell therapy - manufactured individually for each patient - is costly and hard to scale.

What Comes Next

The catalyst list is short. Initial preclinical animal data for INB-619 is due in the second half of 2026 - the readout tied to the contingent tranche - alongside further FDA interaction on regulatory pathways for DeltEx DRI.

An INB-100 update, covering the gamma-delta programme in acute leukaemia patients undergoing stem-cell transplant at the University of Kansas Cancer Center, is guided for a scientific meeting in late 2026, with more DeltEx DRI updates flagged for later this year.

Conclusion

IN8bio's published data is genuinely compelling for a disease that has barely moved the needle in two decades, doubling progression-free survival with no dose-limiting toxicities is the kind of signal that attracts serious regulatory and partnering interest. The financing structure is unusually clever for a cash-strapped biotech, tying a second $20.1 million tranche to preclinical milestones rather than requiring an open-market raise into a roughly $12 million valuation. But that structure also means the near-term determinant of the balance sheet isn't the brain-cancer data at all, it's an unrelated laboratory readout for INB-619 due in the second half of 2026, making that milestone more consequential to watch than any further glioblastoma updates.